Pirfenidone suppresses MAPK signalling pathway to reverse epithelial‐mesenchymal transition and renal fibrosis

Abstract

These results suggest that pirfenidone is able to attenuate EMT and fibrosis in vivo and in vitro through antagonizing the MAPK pathway, providing a potential treatment to alleviate renal tubulointerstitial fibrosis.